+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Regional Outlook and Forecast, 2021-2027

  • PDF Icon

    Report

  • 167 Pages
  • February 2022
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5571071
Description Jump to:
The Global Benign Prostatic Hyperplasia Therapeutics Market size is expected to reach $7.4 billion by 2027, rising at a market growth of 4.6% CAGR during the forecast period.

Benign prostatic hyperplasia (BPH) is a benign swelling of the prostate gland that is not malignant. Benign prostatic hypertrophy or benign prostatic blockages are terms used to describe this ailment. One of the most common conditions in males over the age of 50 is prostate cancer. The hyperplastic alterations in the prostate tissue that result in prostatic enlargement generate BPH symptoms.

The size of men's prostate grows larger as they grow older. As the prostate gland grows larger, it presses against and compresses the urethra and causes thickening of the bladder’s line. The obstruction increases urine outflow resistance and inhibits detrusor muscle responsiveness as a result of the obstruction. This disorder causes difficulty starting to urinate, a weak urine stream, inability to clear the urinary bladder, and increased pee frequency, which is most noticeable at night.

In men under the age of 40, signs and symptoms of prostate gland enlargement are uncommon. By the age of 60, around a third of men have moderate to severe symptoms, and by the age of 80, approximately half of men have them. Genetic background, diabetes as well as cardiovascular disease, and lifestyle are some factors that are responsible for the occurrence of benign prostate hyperplasia.

Moreover, the expiration of patents on major branded products has resulted in the development of various generic drugs, as well as collaboration among key players for the development of new BPH therapeutics for improved drug efficacy and safe therapy for prevailing drugs as well as impending new molecular entities, all of which contribute to the market's growth. The industry has been fueled further by a significant increase in healthcare expenditures around the world.



COVID-19 Impact Analysis


The COVID-19 pandemic caused severe losses to the world in terms of economy as well as healthcare. The pandemic caused a significant number of deaths as well as industrial closure. In addition, the COVID-19 outbreak also resulted in a negative influence on the market for treatments for benign prostatic hyperplasia. A significant number of hospitals and clinics around the world have been reconfigured to boost hospital capacity for COVID-19 patients. However, now that COVID-19 vaccines are accessible, several governments are trying to guarantee that life-saving medications and vaccines are supplied without interruption.

Elective procedures of benign pathology were recommended to be postponed until the burden on the healthcare system from COVID-19 lessened because hospitals is expected to encounter a tremendous demand for resources to combat a likely increase in COVID-19 patients. Surgical operations such as TURP, HoLEP, ThuLEP, and PVP have to be postponed as a result.

Market Growth Factors:


Increasing prevalence of geriatric population


The inconvenience that is caused by benign prostate hyperplasia keeps increasing as the age of a man increases. In addition, the immunity of aged people is comparatively much lower than young people which make them more vulnerable toward hormonal disorders. BPH is hormonally dependent on testosterone and dihydrotestosterone (DHT) production and is considered a typical aspect of male aging. By the age of 60, approximately half of men have histopathologic BPH, and by the age of 85, 90% of men have it.

The evolving lifestyle of people across the world


With the increasing advancement and modernization, the lifestyle of people across the world is also evolving. The number of people that live a sedentary lifestyle is substantially increasing. The adoption of this lifestyle is likely to cause a significant rise in the number of people with obesity. Moreover, obesity is a major cause that facilitates the occurrence of benign prostatic hyperplasia. Due to the increased pressure on the abdominal area while seating, the prostate of a man undergoes extreme pressure and blockage in the blood vessels. This routine of people causes prostate enlargement or benign prostate hyperplasia.

Marketing Restraining Factor:


Side-effects post BPH medications


While both medicines and surgery can be used to treat BPH, both have severe side effects. 5-ARIs (5-alpha reductase inhibitors), Alpha-blockers, and other medication groups are routinely used to treat BPH. Orthostatic hypotension, dizziness, retrograde ejaculation, and rhinitis are all side effects of alpha-blockers. Some of these effects are more common in the elderly people, and they can lead to serious complications such as nausea, vomiting, and diarrhea.



Therapy Outlook


Based on the Therapy, the Benign prostatic hyperplasia therapeutic market is bifurcated into Mono drug therapy and Combination drug therapy. In 2020, the combination therapy recorded a substantial revenue share of the benign prostatic hyperplasia therapeutics market. The increased growth of this segment is attributed to multiple factors such as a wider range of antibiotics, colistin monotherapy having lesser effectiveness than beta-lactam monotherapy, and in vitro data demonstrating antibiotic combinations' synergy.

Therapeutics Class Outlook


Based on the Therapeutic class, the Benign prostatic hyperplasia therapeutic market is segmented into Alpha blockers, 5- alpha reductase inhibitors, Phosphodiesterase-5 inhibitors, and Others. In 2020, the 5- Alpha Reductase Inhibitors segment procured a substantial revenue share of the benign prostatic hyperplasia therapeutics market. Only men with confirmed prostate enlargement should use 5-alpha reductase inhibitors. 5-alpha-reductase inhibitors are a class of medications that are used to treat benign prostatic hyperplasia (enlarged prostate) and male pattern hair loss.

Regional Outlook


Based on the Region, the benign prostatic hyperplasia therapeutic market is analyzed across North America, Europe, APAC, LAMEA. In 2020, North America accounted for the largest revenue share of the benign prostatic hyperplasia therapeutics market. The increased growth of the market across this region is attributed to the robust healthcare infrastructure of the countries across the region. Countries like the US, Mexico, and Canada comprise established healthcare facilities. Moreover, the increased focus of the people toward their health is another major reason for the growth of the market across North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.

Scope of the Study


Market Segments Covered in the Report:


By Therapy
  • Mono Drug Therapy
  • Combination Drug Therapy

By Therapeutics Class
  • Alpha Blockers
  • 5- alpha Reductase Inhibitors
  • Phosphodiesterase-5 Inhibitors
  • Others

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players


List of Companies Profiled in the Report:

  • GlaxoSmithKline PLC (GSK)
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • Allergan PLC (AbbVie)
  • Merck Group (Merck Sharp & Dohme Corp.)
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceuticals Industries Ltd.
  • Sanofi S.A.
  • Pfizer, Inc.
  • Abbott Laboratories

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
1.4.2 Global Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
1.4.3 Global Benign Prostatic Hyperplasia Therapeutics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Benign Prostatic Hyperplasia Therapeutics Market by Therapy
3.1 Global Mono Drug Therapy Market by Region
3.2 Global Combination Drug Therapy Market by Region
Chapter 4. Global Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
4.1 Global Alpha Blockers Market by Region
4.2 Global 5- alpha Reductase Inhibitors Market by Region
4.3 Global Phosphodiesterase-5 Inhibitors Market by Region
4.4 Global Others Market by Region
Chapter 5. Global Benign Prostatic Hyperplasia Therapeutics Market by Region
5.1 North America Benign Prostatic Hyperplasia Therapeutics Market
5.1.1 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.1.1 North America Mono Drug Therapy Market by Country
5.1.1.2 North America Combination Drug Therapy Market by Country
5.1.2 North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.1.2.1 North America Alpha Blockers Market by Country
5.1.2.2 North America 5- alpha Reductase Inhibitors Market by Country
5.1.2.3 North America Phosphodiesterase-5 Inhibitors Market by Country
5.1.2.4 North America Others Market by Country
5.1.3 North America Benign Prostatic Hyperplasia Therapeutics Market by Country
5.1.3.1 US Benign Prostatic Hyperplasia Therapeutics Market
5.1.3.1.1 US Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.3.1.2 US Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.1.3.2 Canada Benign Prostatic Hyperplasia Therapeutics Market
5.1.3.2.1 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.3.2.2 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.1.3.3 Mexico Benign Prostatic Hyperplasia Therapeutics Market
5.1.3.3.1 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.3.3.2 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.1.3.4 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market
5.1.3.4.1 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.3.4.2 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2 Europe Benign Prostatic Hyperplasia Therapeutics Market
5.2.1 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.1.1 Europe Mono Drug Therapy Market by Country
5.2.1.2 Europe Combination Drug Therapy Market by Country
5.2.2 Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2.2.1 Europe Alpha Blockers Market by Country
5.2.2.2 Europe 5- alpha Reductase Inhibitors Market by Country
5.2.2.3 Europe Phosphodiesterase-5 Inhibitors Market by Country
5.2.2.4 Europe Others Market by Country
5.2.3 Europe Benign Prostatic Hyperplasia Therapeutics Market by Country
5.2.3.1 Germany Benign Prostatic Hyperplasia Therapeutics Market
5.2.3.1.1 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.3.1.2 Germany Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2.3.2 UK Benign Prostatic Hyperplasia Therapeutics Market
5.2.3.2.1 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.3.2.2 UK Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2.3.3 France Benign Prostatic Hyperplasia Therapeutics Market
5.2.3.3.1 France Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.3.3.2 France Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2.3.4 Russia Benign Prostatic Hyperplasia Therapeutics Market
5.2.3.4.1 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.3.4.2 Russia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2.3.5 Spain Benign Prostatic Hyperplasia Therapeutics Market
5.2.3.5.1 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.3.5.2 Spain Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2.3.6 Italy Benign Prostatic Hyperplasia Therapeutics Market
5.2.3.6.1 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.3.6.2 Italy Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2.3.7 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market
5.2.3.7.1 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.3.7.2 Rest of Europe Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market
5.3.1 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.1.1 Asia Pacific Mono Drug Therapy Market by Country
5.3.1.2 Asia Pacific Combination Drug Therapy Market by Country
5.3.2 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3.2.1 Asia Pacific Alpha Blockers Market by Country
5.3.2.2 Asia Pacific 5- alpha Reductase Inhibitors Market by Country
5.3.2.3 Asia Pacific Phosphodiesterase-5 Inhibitors Market by Country
5.3.2.4 Asia Pacific Others Market by Country
5.3.3 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country
5.3.3.1 China Benign Prostatic Hyperplasia Therapeutics Market
5.3.3.1.1 China Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.3.1.2 China Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3.3.2 Japan Benign Prostatic Hyperplasia Therapeutics Market
5.3.3.2.1 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.3.2.2 Japan Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3.3.3 India Benign Prostatic Hyperplasia Therapeutics Market
5.3.3.3.1 India Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.3.3.2 India Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3.3.4 South Korea Benign Prostatic Hyperplasia Therapeutics Market
5.3.3.4.1 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.3.4.2 South Korea Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3.3.5 Singapore Benign Prostatic Hyperplasia Therapeutics Market
5.3.3.5.1 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.3.5.2 Singapore Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3.3.6 Malaysia Benign Prostatic Hyperplasia Therapeutics Market
5.3.3.6.1 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.3.6.2 Malaysia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3.3.7 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market
5.3.3.7.1 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.3.7.2 Rest of Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4 LAMEA Benign Prostatic Hyperplasia Therapeutics Market
5.4.1 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.1.1 LAMEA Mono Drug Therapy Market by Country
5.4.1.2 LAMEA Combination Drug Therapy Market by Country
5.4.2 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4.2.1 LAMEA Alpha Blockers Market by Country
5.4.2.2 LAMEA 5- alpha Reductase Inhibitors Market by Country
5.4.2.3 LAMEA Phosphodiesterase-5 Inhibitors Market by Country
5.4.2.4 LAMEA Others Market by Country
5.4.3 LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country
5.4.3.1 Brazil Benign Prostatic Hyperplasia Therapeutics Market
5.4.3.1.1 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.3.1.2 Brazil Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4.3.2 Argentina Benign Prostatic Hyperplasia Therapeutics Market
5.4.3.2.1 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.3.2.2 Argentina Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4.3.3 UAE Benign Prostatic Hyperplasia Therapeutics Market
5.4.3.3.1 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.3.3.2 UAE Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4.3.4 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market
5.4.3.4.1 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.3.4.2 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4.3.5 South Africa Benign Prostatic Hyperplasia Therapeutics Market
5.4.3.5.1 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.3.5.2 South Africa Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4.3.6 Nigeria Benign Prostatic Hyperplasia Therapeutics Market
5.4.3.6.1 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.3.6.2 Nigeria Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4.3.7 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market
5.4.3.7.1 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.3.7.2 Rest of LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Astellas Pharma, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Allergan PLC (AbbVie)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.5 Merck Group (Merck Sharp & Dohme Corp.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Boehringer Ingelheim International Gmbh
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expenses
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Sanofi S.A.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Abbott Laboratories
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense

Companies Mentioned

  • GlaxoSmithKline PLC (GSK)
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • Allergan PLC (AbbVie)
  • Merck Group (Merck Sharp & Dohme Corp.)
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceuticals Industries Ltd.
  • Sanofi S.A.
  • Pfizer, Inc.
  • Abbott Laboratories

Methodology

Loading
LOADING...

Related Topics

Related Reports

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 97 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type - Product Image

Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

  • Report
  • 96 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Treatment Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Benign Prostatic Hyperplasia (BPH) Treatment Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 151 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.